XELJANZÂ tofacitinib citrate Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis

Pfizer Inc. NYSEPFE announced today that the European Commission EC has approved XELJANZÂ tofacitinib citrate 10 mg twicedaily BID for at least eight weeks followed by XELJANZ 5 mg BID or 10 mg BID for the treatment of adult patient...